Vetoquinol SA

Paris Stock Exchange VETO.PA

Vetoquinol SA Price to Earnings Ratio (P/E) on January 14, 2025: 14.52

Vetoquinol SA Price to Earnings Ratio (P/E) is 14.52 on January 14, 2025, a -35.23% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Vetoquinol SA 52-week high Price to Earnings Ratio (P/E) is 23.18 on January 24, 2024, which is 59.66% above the current Price to Earnings Ratio (P/E).
Vetoquinol SA 52-week low Price to Earnings Ratio (P/E) is 14.52 on January 14, 2025, which is 0.00% below the current Price to Earnings Ratio (P/E).
Vetoquinol SA average Price to Earnings Ratio (P/E) for the last 52 weeks is 19.65.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Paris Stock Exchange: VETO.PA

Vetoquinol SA

CEO	Mr. Alain Masson
IPO Date	Nov. 17, 2006
Location	France
Headquarters	Magny-Vernois
Employees	2,519
Sector	Health Care
Industries Pharmaceuticals

Description

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.

Key trends

Past 5 years